Glycoprotein News and Research

RSS

A common cold may boost the immune system against COVID-19

A recent groundbreaking research paper published in the journal Nature Communications reveals the association of circulating SARS-CoV-2-specific T cells at exposure with lack of infection – implying the protective role for cross-reactive immune T cells in coronavirus disease 2019 (COVID-19) and opening the door for second-generation vaccines that could circumvent spike-antibody immune escape variants.

11 Jan 2022

Exploring the kinetics of SARS-CoV-2 Marseille-4 variant

In a new study, researchers determined the nature and dynamics of mutations associated with the SARS-CoV-2 French Marseille-4 variant during 10 months from its onset, and concluded that the heterogenicity associated with a SARS-CoV-2 lineage can possibly predict the end of an outbreak.

11 Jan 2022

Mapping peripheral blood glycoprotein profiles of COVID-19 patients

A team of researchers recently analyzed differential protein glyco-isoform distributions of symptomatic and asymptomatic coronavirus disease 2019 patients.

11 Jan 2022

SARS-CoV-2 shown to spread through cell-to-cell transmission

A new study investigated SARS-CoV-2 cell-to-cell transmission in the context of cell-free infection and compared it to SARS-CoV.

10 Jan 2022

SARS-CoV-2 spike engagement of ACE2 shown to prime S2′ site cleavage and fusion initiation

In a new study, researchers used a cell-cell fusion assay to extract potentially cleaved spike protein products from syncytia in order to explore the functional and biochemical characteristics of spike (S) protein when it engages its receptor ACE2 in living cells.

10 Jan 2022

Bolstering current therapeutic antibody treatments to help fight Omicron infections

Researchers test the neutralizing action of a panel of eight therapeutic monoclonal antibodies against the SARS-CoV-2 Omicron (B.1.1.529) variant.

9 Jan 2022

Broad cross-neutralization antibodies found to be effective against SARS-CoV-2 Omicron variant

A new study aimed to explore whether there is a way to induce the production of potent neutralizing antibodies capable of neutralizing all SARS-CoV-2 variants - including Omicron.

7 Jan 2022

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

In a recently published article in the journal Nano-Micro Letters, scientists have provided an in-depth review on the application and benefits of nanotechnology in the development of coronavirus disease 2019 (COVID-19) vaccines.

7 Jan 2022

Researchers outline characteristics of Omicron variant immune escape and viral entry into host cells

A new study found that the Omicron variant contains a number of mutations that decrease neutralizing antibody activity and immune escape.

6 Jan 2022

Small molecule identified as a SARS-CoV-2 inhibitor

A new study published in iScience reports the results of a screening strategy to identify small molecules that target viral entry to block infection with this virus.

6 Jan 2022

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Researchers determine the cross-reactivity of the SARS-CoV-2 spike glycoprotein-induced antibodies before and after a third SARS-CoV-2 vaccine dose.

5 Jan 2022

Oral bacteria-based SARS-CoV-2 vaccine platform

In a new study, researchers engineered the bacterial strain, Salmonella, to express differently-sized antigens to serve as vaccine platforms.

5 Jan 2022

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

5 Jan 2022